pimecrolimus is a topical immunomodulatory medication that is used for the treatment of atopic dermatitis (eczema). It works by inhibiting the activity of T-lymphocytes, a type of white blood cell that plays a vital role in the immune response. pimecrolimus explicitly inhibits T-lymphocyte activation by blocking the production of cytokine signaling molecules involved in the immune response
By inhibiting the activity of T-lymphocytes and the production of cytokines, pimecrolimus can help to reduce inflammation and itching associated with atopic dermatitis. It also helps restore the skin barrier function, which is often compromised in patients with atopic dermatitis
pimecrolimus. It has a narrow spectrum of activity and is primarily effective against T-lymphocytes involved in the skin’s immune response. It is effective in the treatment of atopic dermatitis in both adults and children and has been approved by the US FDA for use in patients aged two years and older.